Tag Archives: ben catherine ivy foundation

Healthcare Leadership Awards 2015_38

Az Business honors winners of Healthcare Leadership Awards

Az Business magazine honored winners of the 2015 Healthcare Leadership Awards Thursday in front of a packed house at the Arizona Grand Resort.

“The Healthcare Leadership Awards honor the women, men and institutions whose passion and innovation are saving lives, extending lives, and improving the quality of our lives,” said Cheryl Green, publisher for AZ Big Media, which publishes Az Business magazine.

Sponsors included Blue Cross Blue Shield of Arizona, Arizona Central Credit Union and CodeRed-I.

Here are the winners of the 2015 Healthcare Leadership Awards:

Healthcare advocate/educator of the year: Catherine Ivy, Ben & Catherine Ivy Foundation

Behavioral health company of the year: Southwest Behavioral Health Services

Bioscience company of the year: VisionGate

Insurance provider of the year: Blue Cross Blue Shield of Arizona

Legal advocate of the year: Martin L. Shultz, Brownstein Hyatt Farber Schreck

Medical company of the year: SynCardia

Medical research company of the year: Barrow Neurological Institute

Researcher of the year: Dr. Daniel D. Von Hoff, TGen and HonorHealth

Physician of the year: Robert J. Arceci, M.D., Phoenix Children’s Hospital

Healthcare executive of the year: Tim Bricker, Chandler Regional and Mercy Gilbert medical centers

Medical center or hospital of the year: Cancer Treatment Centers of America at Western Regional Medical Center

Lifetime achievement award: Peter Fine, Banner Health

“The word visionary is thrown around often, but it’s not often that it really fits,” said Michael Gossie, editor in chief for Az Business magazine. “But that’s not the case with Peter Fine. He is a visionary. And it took a visionary to take two healthcare systems with very different histories and grow it into a healthcare company that generates more than $5 billion in annual revenue, operates 28 acute-care hospitals across seven states, and employs more than 45,000 employees in Arizona.”


Healthcare Leadership Awards 2015 Photos

Healthcare Leadership Awards 2015_12
Healthcare Leadership Awards 2015_12
Healthcare Leadership Awards 2015_12
Healthcare Leadership Awards 2015_14
Healthcare Leadership Awards 2015_14
Healthcare Leadership Awards 2015_14
Healthcare Leadership Awards 2015_13
Healthcare Leadership Awards 2015_13
Healthcare Leadership Awards 2015_13
Healthcare Leadership Awards 2015_06
Healthcare Leadership Awards 2015_06
Healthcare Leadership Awards 2015_06
Healthcare Leadership Awards 2015_07
Healthcare Leadership Awards 2015_07
Healthcare Leadership Awards 2015_07
Healthcare Leadership Awards 2015_08
Healthcare Leadership Awards 2015_08
Healthcare Leadership Awards 2015_08
Healthcare Leadership Awards 2015_15
Healthcare Leadership Awards 2015_15
Healthcare Leadership Awards 2015_15
Healthcare Leadership Awards 2015_16
Healthcare Leadership Awards 2015_16
Healthcare Leadership Awards 2015_16
Healthcare Leadership Awards 2015_02
Healthcare Leadership Awards 2015_02
Healthcare Leadership Awards 2015_02
Healthcare Leadership Awards 2015_09
Healthcare Leadership Awards 2015_09
Healthcare Leadership Awards 2015_09
Healthcare Leadership Awards 2015_10
Healthcare Leadership Awards 2015_10
Healthcare Leadership Awards 2015_10
Healthcare Leadership Awards 2015_11
Healthcare Leadership Awards 2015_11
Healthcare Leadership Awards 2015_11
Healthcare Leadership Awards 2015_04
Healthcare Leadership Awards 2015_04
Healthcare Leadership Awards 2015_04
Healthcare Leadership Awards 2015_05
Healthcare Leadership Awards 2015_05
Healthcare Leadership Awards 2015_05
Healthcare Leadership Awards 2015_01
Healthcare Leadership Awards 2015_01
Healthcare Leadership Awards 2015_01
Healthcare Leadership Awards 2015_17
Healthcare Leadership Awards 2015_17
Healthcare Leadership Awards 2015_17
Healthcare Leadership Awards 2015_18
Healthcare Leadership Awards 2015_18
Healthcare Leadership Awards 2015_18
Healthcare Leadership Awards 2015_19
Healthcare Leadership Awards 2015_19
Healthcare Leadership Awards 2015_19
Healthcare Leadership Awards 2015_20
Healthcare Leadership Awards 2015_20
Healthcare Leadership Awards 2015_20
Healthcare Leadership Awards 2015_21
Healthcare Leadership Awards 2015_21
Healthcare Leadership Awards 2015_21
Healthcare Leadership Awards 2015_22
Healthcare Leadership Awards 2015_22
Healthcare Leadership Awards 2015_22
Healthcare Leadership Awards 2015_23
Healthcare Leadership Awards 2015_23
Healthcare Leadership Awards 2015_23
Healthcare Leadership Awards 2015_24
Healthcare Leadership Awards 2015_24
Healthcare Leadership Awards 2015_24
Healthcare Leadership Awards 2015_25
Healthcare Leadership Awards 2015_25
Healthcare Leadership Awards 2015_25
Healthcare Leadership Awards 2015_26
Healthcare Leadership Awards 2015_26
Healthcare Leadership Awards 2015_26
Healthcare Leadership Awards 2015_27
Healthcare Leadership Awards 2015_27
Healthcare Leadership Awards 2015_27
Healthcare Leadership Awards 2015_28
Healthcare Leadership Awards 2015_28
Healthcare Leadership Awards 2015_28
Healthcare Leadership Awards 2015_29
Healthcare Leadership Awards 2015_29
Healthcare Leadership Awards 2015_29
Healthcare Leadership Awards 2015_30
Healthcare Leadership Awards 2015_30
Healthcare Leadership Awards 2015_30
Healthcare Leadership Awards 2015_31
Healthcare Leadership Awards 2015_31
Healthcare Leadership Awards 2015_31
Healthcare Leadership Awards 2015_32
Healthcare Leadership Awards 2015_32
Healthcare Leadership Awards 2015_32
Healthcare Leadership Awards 2015_33
Healthcare Leadership Awards 2015_33
Healthcare Leadership Awards 2015_33
Healthcare Leadership Awards 2015_34
Healthcare Leadership Awards 2015_34
Healthcare Leadership Awards 2015_34
Healthcare Leadership Awards 2015_35
Healthcare Leadership Awards 2015_35
Healthcare Leadership Awards 2015_35
Healthcare Leadership Awards 2015_36
Healthcare Leadership Awards 2015_36
Healthcare Leadership Awards 2015_36
Healthcare Leadership Awards 2015_37
Healthcare Leadership Awards 2015_37
Healthcare Leadership Awards 2015_37
Healthcare Leadership Awards 2015_38
Healthcare Leadership Awards 2015_38
Healthcare Leadership Awards 2015_38
Healthcare Leadership Awards 2015_39
Healthcare Leadership Awards 2015_39
Healthcare Leadership Awards 2015_39
Healthcare Leadership Awards 2015_40
Healthcare Leadership Awards 2015_40
Healthcare Leadership Awards 2015_40
Healthcare Leadership Awards 2015_41
Healthcare Leadership Awards 2015_41
Healthcare Leadership Awards 2015_41
Healthcare Leadership Awards 2015_42
Healthcare Leadership Awards 2015_42
Healthcare Leadership Awards 2015_42

healthcare

Az Business names Healthcare Leadership Awards finalists

Each year, AZ Business magazine hosts the Healthcare Leadership Awards to honor the women, men and institutions that bring excellence and innovation to Arizona’s healthcare sector.

Az Business is proud to announce the 2015 Healthcare Leadership Awards finalists, who were chosen by a panel of industry experts and will be recognized at the Healthcare Leadership Awards dinner and awards ceremony on April 9  at the Arizona Grand Resort. The finalists, in alphabetical order, are:

Abrazo Health — Arrowhead Hospital

Abrazo Health — Michele Finney

Affiliated Urologists — Dr. Mark Hong

Banner Health, Cardon Children’s Medical Center — Rachel Calendo

Banner Health — Peter Fine

Ben & Catherine Ivy Foundation — Catherine Ivy

Blue Cross Blue Shield of Arizona

Brownstein Hyatt Farber Schreck — Martin L. Shultz

Cancer Treatment Centers of America at Western Regional Medical Center

CTCA — Dr. Glen Weiss

Dedicated Health Solutions

Dignity Health — Barrow Neurological Institute

Dignity Health, Chandler Regional and Mercy Gilbert medical centers — Tim Bricker

Dignity Health — St. Joseph’s Hospital and Medical Center

HonorHealth and TGen — Dr. Daniel D. Von Hoff

HonorHealth – Virginia G. Piper Cancer Center

IASIS Healthcare — Tony Marinello

Insys Therapeutics

Magellan Health

Maricopa Integrated Health System — Dr. David Wisinger

Medtronic

Midwestern University — Kathleen Goeppinger

Quarles & Brady — Roger Morris

Phoenix Children’s Hospital – Dr. Robert J. Arceci

Radiant Research

Remuda Ranch

Snell and Wilmer – Richard Mallery

Sonora Quest Laboratories

Southwest Behavioral Health Services

SynCardia Systems

The CORE Institute — Dr. David Jacofsky

UnitedHealthcare of Arizona

University of Arizona Cancer Center

VisionGate

brain

TGen-Ivy Foundation brain cancer trial approved

In 2012, The Ben & Catherine Ivy Foundation awarded $10 million in grants for two groundbreaking brain cancer research projects at the Translational Genomics Research Institute (TGen). One of those projects has officially received the final regulatory approval from University of California, San Francisco, which means patient enrollment for the trial can begin.

In the $5-million-project, “Genomics Enabled Medicine in Glioblastoma Trial,” TGen and its clinical partners will lead first-in-patient clinical trial studies that will test promising new drugs that might extend the survival of GBM patients. This multi-part study will take place in clinics across the country and TGen laboratories.

“GBM is one of the top three fastest-killing cancers out there and it affects people of all ages,” said Catherine (Bracken) Ivy, founder and president of The Ben & Catherine Ivy Foundation. “It is critical that we fund research that will help patients live longer so we can study and treat brain cancer.”

The project begins with a pilot study of 15 patients, using whole genome sequencing to study their tumor samples to help physicians determine what drugs might be most beneficial.

To support molecularly informed clinical decisions, TGen labs also will examine genomic data from at least 536 past cases of glioblastoma, as well as tumor samples from new cases, developing tools that will produce more insight into how glioblastoma tumors grow and survive. TGen also will conduct a series of pioneering lab tests to measure cell-by-cell responses to various drugs.

“GBM is a disease that needs answers now, and we strongly believe those answers will be found in the genome,” said Dr. David Craig, TGen’s Deputy Director of Bioinformatics, Director of TGen’s Neurogenomics Division, and one of the projects principal investigators. “Identifying the genes that contribute to the survival of glioblastoma will provide valuable information on how to treat it, and may also lead to an improved understanding of what drives other cancers as well.”

To get new treatments to patients as quickly as possible, this five-year study will include a feasibility study involving up to 30 patients, followed by Phase II clinical trials with as many as 70 patients. TGen is teaming with the Ivy Early Phase Clinical Trials Consortium that includes: University of California, San Francisco; University of California, Los Angeles; the MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; University of Utah; and the Dana-Farber/Harvard Cancer Center.

The results of these clinical trials should not only help the patients who join them, but also provide the data needed for FDA approval and availability of new drugs that could benefit tens of thousands of brain cancer patients in the future.

“Working with physicians, the project will aim to understand treatment in the context of the tumor’s molecular profile. We will have the opportunity to determine when combinations of drugs might be more effective than using a single drug, quickly identify which therapies don’t work, and accelerate discovery of ones that might prove promising for future development,” said Dr. John Carpten, TGen’s Deputy Director of Basic Science, Director of TGen’s Integrated Cancer Genomics Division, and another of the project’s principal investigators.

In addition to helping patients as quickly as possible, the project should significantly expand Arizona’s network of brain cancer experts.

banner alzheimers foundation - brain research

Ivy Foundation Grants $1.2 Million for Brain Cancer Study

The Ben & Catherine Ivy Foundation (Ivy Foundation) announced a gift of nearly $1.2 million to study brain tumor vaccines that combine a patient’s immune stimulators with tumor cultures from other patients.

The Ivy Foundation selected the study led by Allan B. Dietz, Ph.D., head of Mayo Clinic’s Human Cellular Therapy Laboratory, and Ian Parney, M.D. Ph.D., a neurosurgeon and immunobiologist, because of Dr. Dietz’s track record in brain cancer research, among other things.

“Mayo Clinic was selected as one of our brain cancer research partners because of the merit of the historical research done by Dr. Dietz and their ability to execute the project,” said Catherine Ivy, founder and president of the Ivy Foundation. “We believe this creative project will contribute important information to brain cancer research.”

The study will combine a patient’s optimized dendritic cells, known to be potent immune stimulators, with pooled and well-characterized cellular debris – known as lysates – from other patients’ brain tumor cultures to generate a tumor vaccine.

“We are combining this new approach with new methods for monitoring and tracking changes in the immune system,” said Dr. Dietz. “Together, we believe that this approach will allow us to identify and treat those patients most likely to benefit from this therapy.”

The Ivy Foundation has a research funding focus on glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors in adults, and is the largest privately funded brain cancer research foundation in North America.

“We are extremely grateful for the Ivy Foundation’s support for our brain tumor vaccine clinical trial,” said Dr. Parney. “Their help has been crucial to bringing this promising new experimental treatment to patients diagnosed with glioblastoma. With their assistance, we hope to improve the outlook for patients with this highly aggressive brain cancer.”

prevention trial - brain scan images

Ivy Foundation Grants Over $9M for Brain Cancer Research

The Ben & Catherine Ivy Foundation (Ivy Foundation) announced its 2012 grant recipients, which total more than $9 million in funding for brain cancer research. The Ivy Foundation is the largest privately funded brain cancer research foundation in North America. Catherine Ivy is the founder and president of the Ivy Foundation, which has a research funding focus on glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors in adults.

The Ivy Foundation awarded the following grants and/or provided funding in 2012:

· $2,500,000 over three years:  Principal Investigator, Greg D. Foltz, M.D., Director, The Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Medical Center
· $5,000,000 over five years:  Principal Investigators, John Carpten, Ph.D. and David Craig, Ph.D., Translational Genomics Research Institute (TGen) – a collaborative effort with University of California, San Francisco; University of California, Los Angeles; Memorial Sloan-Kettering Cancer Center; Massachusetts General Hospital; Dana Farber/Harvard Cancer Center; MD Anderson; and University of Utah
· $45,000 annually: Principal Investigator, Brandy Wells, Translational Genomics Research Institute (TGen), for the Ivy Neurological Sciences Internship program
· Over $2 million paid out in 2012 for previously committed multi-year brain cancer research grants

“We are encouraged and remain strongly committed to moving the progress forward for patients diagnosed with brain cancer,” said Ivy. “The 2012 Ivy Foundation grant recipients are important strategic partners in our objective to double the life expectancy of people diagnosed with GBM within the next seven years.”

Bioscience helix

Ivy Foundation Renews Support for TGen Program

The Arizona-based Ben & Catherine Ivy Foundation will fund a second year of the Ivy Neurological Science Internship Program at the Translational Genomics Research Institute (TGen).

The internship program offers hands-on biomedical research experience for high school, undergraduate and aspiring medical school students pursuing careers in brain tumor research, neuroscience and neurogenomics.

Through the program, world-class scientific investigators at TGen guide interns in the translational process of moving laboratory discoveries along the pipeline into new treatments for patients in clinical trials.

“Based upon the success of the 2012 pilot year, we believe the Ivy Neurological Science Internship Program at TGen will inspire a new generation of leaders in this field,” said Catherine Ivy, President of The Ben & Catherine Ivy Foundation. “There is an urgent and continuing need to encourage research into the intricate workings of brain cancer.”

TGen will select seven students for the program this year. Starting in June, two high-school students will participate in a 10-week summer program. Four undergraduate students will spend the fall semester at TGen, and one student planning to attend medical school will participate for a full academic year, beginning in the fall.

“Development of a local, knowledge-based workforce depends on educating and training talented students in the latest aspects of biomedical research and medicine,” said TGen President Dr. Jeffrey Trent. “The continued support from the Ivy program greatly enhances our efforts to provide hands-on experience in the area of translational research.”

In addition to brain tumor and neurological sciences research experience, Ivy interns will participate in a clinical training module that will engage them with the ultimate focus of these studies – the patient.

“TGen recognizes that we must invest in the development of the next generation of researchers and physicians; we need to prepare today’s students for the complex and challenging work awaiting them in the areas of brain tumor and neurological sciences research,” said Brandy Wells, Manager of TGen’s Education and Outreach.

For more information, please contact Brandy Wells at bwells@tgen.org or 602-343-8655.

brain cancer

Nation’s Largest Brain Cancer Foundation Moves To Scottsdale

The largest privately funded national foundation focusing solely on brain cancer research has moved from the San Francisco Bay area (Palo Alto, Calif.) to Scottsdale. The Ben and Catherine Ivy Foundation is dedicated to funding research that improves the survival and quality of life for people with brain cancer, which are known as gliomas. Since 2005, it has contributed more than $50 million to brain cancer research in the United States and Canada, with much more funding planned.

“There is a cluster of excellent research institutions located in Phoenix, such as TGen, Barrow Neurological Institute and St. Joseph’s Hospital, with growing potential to make critical strides in brain cancer research,” said Founder and Board President Catherine Ivy, of the Ben and Catherine Ivy Foundation. “Funding these institutions and encouraging collaborations will enhance the funding we have done previously and move us closer to our goal: Doubling the survival rate of people diagnosed with gliomas within seven years from now.”

The Ben and Catherine Ivy Foundation was created in 2005 after Ben Ivy was diagnosed with a glioblastoma (GBM) and passed away four months later. A broad variety of tumors can form in the brain causing evident symptoms and approximately 40 percent of these will be diagnosed as GBM, the most aggressive form of brain cancer. Several well-known people have lost their lives due to GBM, including Senator Ted Kennedy in 2009 and Wall Street billionaire and CEO of IMG Worldwide Ted Forstmann in 2011.

Catherine Ivy is a native of Phoenix, where she grew up before moving to Palo Alto, Calif., for several years.

For more information on the Ben and Catherine Ivy Foundation, visit the Ivy Foundation’s website at ivyfoundation.org.